Physician profile
Jonathan E Hall
NPI 1811912967
$7,008.37
in general payments reported to CMS, 2019-2025
44 companies · $1,261 in 2025
The $1,261 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774 · 2020: $824 · 2021: $825 · 2022: $779 · 2023: $1,243 · 2024: $1,303 · 2025: $1,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,806.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,056.78 | 2021-2025 | |
| Novo Nordisk INC | $712.16 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $580.78 | 2019-2025 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $566.38 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $538.06 | 2019-2025 | |
| Lilly USA, LLC | $464.03 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $418.68 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Shield Therapeutics INC | $388.20 | 2023-2024 | Accrufer |
| Sanofi-Aventis U.S. LLC | $250.71 | 2019-2024 | |
| Amgen INC. | $165.55 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $147.79 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Teva Pharmaceuticals USA, INC. | $134.24 | 2019-2020 | |
| Exact Sciences Corporation | $133.32 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $118.52 | 2022-2024 | Rexulti |
| Axsome Therapeutics, INC. | $101.81 | 2024-2025 | Auvelity |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.